.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its leading biopharma selection for 2025 as well as rated another nine names in the area as overweight. The investment banking company pointed out in a details that it continues to strongly believe “diabesity is actually readied to become.